MedTrace Logo

Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy.

NCT00422955 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2016-09-15

No results posted yet for this study

Summary

Fluid management study in patients with type 2 diabetes and autonomic neuropathy.

Conditions

  • Neuropathy, Diabetic

Interventions

DRUG

rosiglitazone

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Primary Completion
2005-10-31
Completion
2005-10-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00422955 on ClinicalTrials.gov